anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a sodium cantharidinate sustained release preparation and a preparation method of the sodium cantharidinate sustained release preparation. The sustained release preparation is prepared from sodium cantharidinate, a sustained release framework material, filler, a disintegrating agent, an adhesive and a lubricant by taking sodium cantharidinate as an active component. The preparation comprises the following components in percentage by weight: 0.5-5% of sodium cantharidinate, 15-50% of sustained release preparation, 10-80% of filler, 0-10% of disintegrating agent, 5-12% of adhesive and 0.5-5% of lubricant. The preparation method comprises the following steps: 1) weighing the sodium cantharidinate, sustained release preparation, filler and disintegrating agent in formula amount, sieving, uniformly mixing, adding the adhesive and preparing a soft material by a wet process; 2) drying and straightening wet particles, adding the lubricant and uniformly mixing; and 3) preparing the required sodium cantharidinate sustained release preparation. Compared with the prior art, the delivery times of the sustained release preparation disclosed by the invention can be reduced, the blood concentration can be maintained stable, the effective anti-tumor maintaining time is prolonged, and the side effect is reduced. The preparation is safe to use and the curative effect is superior to that of a common preparation.
INTRODUCTION: Management of infection on internal fixation hardware is particularly complex. The main aim of the present study was to assess bone consolidation rates under septic conditions in patients treated for bone and joint infection (BJI) with hardware retention. Secondary objectives were to determine a time limit beyond which it is unreasonable to retain hardware, and to assess risk factors for non-consolidation and functional results. The study hypothesis was that bone consolidation is possible under septic conditions without hardware exchange.
MATERIAL AND METHOD: A single-center retrospective observational study was conducted on 69 patients for the period January 1, 2009 to December 31, 2019. We included all patients aged over 15 years with infection after internal fixation or fusion whose files had been discussed in the multidisciplinary team meeting during the study period. Bone healing was screened for on X-ray or CT. Study data comprised type of fracture, smoking status, time to treatment for open fracture, initial surgery time, type of hardware, interval between fixation and revision, and type of irrigation. Functional results were assessed at follow-up: walking, pain, return to work and SF12 and QuickDASH scores.
RESULTS: The bone healing rate was 73.5% (50/68 patients) at a mean 24 weeks (range, 6-68 weeks). Time to revision did not significantly impact consolidation: 60% for 2 weeks (6/10 cases), 80% for 2-10 weeks (35/40 cases), and 64% for >10 weeks (9/14 cases) (p = 0.28). Smoking, longer initial surgery time and Gustilo type IIIb or IIIc were significant risks factors for non-consolidation.
DISCUSSION: Bone consolidation under septic conditions with hardware retention adhering to an established medical and surgical protocol was reliable and straightforward, without extra morbidity. These findings are encouraging, and in line with the literature. We were unable to determine a time limit beyond which hardware prevented healing.
LEVEL OF EVIDENCE: IV; descriptive epidemiological study.
The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the heavy chain or/and the light chain comprises one or more first recognition sites for transglutaminase (KalbTG) from Coutts nigella albus or a functionally active variant thereof. The one or more first recognition sites are introduced at one or more selected positions within the heavy and/or light chain of the antibody. The invention further relates to one or more nucleic acids encoding the modified antibodies according to the invention, as well as covalent conjugates comprising (i) the modified antibodies according to the invention and (ii) one or more non-antibody moieties (payloads) covalently conjugated to the one or more first recognition sites directly or via a first linker. In certain embodiments, the non-antibody moiety comprises a therapeutic entity and optionally a second linker. The invention further relates to a method of covalently conjugating a modified antibody according to the invention to a non-antibody moiety. Where the non-antibody moiety comprises a therapeutic entity, the invention further relates to a conjugate of a modified antibody according to the invention and a therapeutic entity as a pharmaceutical composition for use as a medicament and for the treatment of a disease.
Systems and methods are provided for facilitating account payment posting transactions. A computer-implemented method may include receiving, from a computer associated with a healthcare provider, a healthcare payment transaction for a patient, wherein the healthcare payment transaction comprises an identifier for a guarantor of the patient and a total payment amount. The method may also include determining, based at least in part on the guarantor identifier, one or more open medical accounts for the guarantor, the one or more open medical accounts having respective outstanding balances. Furthermore, the method may include comparing the total payment amount with the respective outstanding balances and generating, based at least in part on the comparison, an account payment posting transaction. The account payment posting transaction may indicate respective amounts, of the total payment amount, to be allocated to the one or more open medical accounts. Additionally, the method may include transmitting the account payment posting transaction to the computer associated with the healthcare provider
INTRODUCTION: Treatment of post lung-transplant airway complications is challenging, and treatment with conventional airway stents is associated with adverse events. More recently, biodegradable airway stents (BDS) have been introduced and may be used to reduce these adverse events. In this study we explore the feasibility of treatment with BDS post lung transplant.
METHODS: All patients treated with BDS in The Netherlands were included in this retrospective multicenter study. Feasibility, life span of the stent, occurrence of adverse events, and evolution of lung function were evaluated.
RESULTS: Twelve patients (six malacia and six stenosis) received a total of 57 BDS, ranging from 1 to 10 BDS per patient. Six patients had been pretreated with conventional airway stents. Median stent life span was 112 days (range 66-202). No adverse events occurred during stent placement. In 5 out of 57 stent placements, a single additional bronchoscopy was necessary because of mucus accumulation (n = 4) or excessive granulation tissue (n = 1). All stent naïve patients became airway stent independent after treatment; all patients pretreated with conventional airway stents were still airway stent dependent at the end of follow up.
CONCLUSION: Treatment with BDS is safe and feasible. Adverse events were mild and easily treatable. All patients with initial treatment with BDS were airway stent independent at the end of follow up with a median treatment of 4 BDS.
<P>PROBLEM TO BE SOLVED: To obtain a composition effective in prophylaxis or treatment of Morbillivirus infectious diseases.  <P>SOLUTION: The prophylactic or treating composition for the Morbillivirus infectious diseases comprises a reduced form glutathione or oxidized form glutathione or a pharmacologically acceptable salt thereof. The composition comprises one or more kinds of antioxidants. In the composition, Morbillivirus is measles virus. The composition which is a medicine, a food and drink or an additive for the food and drink is provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To obtain a photopolymerizable surface coating material for dentistry in which a photopolymerization type surface coating material for dentistry is sufficiently polymerized by visible light irradiation when applied to a dental material surface, the surface becomes glossy after curing and the cured surface has excellent durability, abrasion resistance and color fastness.  <P>SOLUTION: This photopolymerization type surface coating material for dentistry comprises a (meth) acrylate monomer, 1-70 wt.% of inorganic fine particles subjected to surface modification with an unsaturated double bond-containing alkoxysilane and having 1-100 nm average particle diameter in a monodispersion state and 0.01-10 pts. wt. of a photopolymerization catalyst based on 100 pts. wt. of the (meth)acrylate and the inorganic particles and has ≤5,000 cP viscosity at 23°C.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To produce a new compound, effective in treating cancers and having pharmacological activities. SOLUTION: This compound is represented by formula I [(m) and (n) are each 0 or 1; X and Y are each H, a halogen, an alkyl, etc.; Z is a 4-12C alkylene in which one or more groups CH2 are substituted with NR, O, etc.; R is H, methyl, etc.; A together with the adjacent C of the benzene ring form the benzene ring, etc.], e.g. N,N'-bis[2 (2-aza-1,3-dioxo-10- methoxycyclopenta[c]phenanthren-2-yl)ethyllethane-1,2-diamine. The compound represented by formula I is produced by reacting a compound represented by formula II with a diamine represented by the formula H2 N-Z-NH2 . The compound can be formulated as a pharmaceutical preparation in a peroral, a parenteral (intravenous or subcutaneous administration) or pernasal administration form and the daily dose thereof is 0.1-400mg administered in one or more divided portions.
A depilatory composition is dispensed from a pressurised container having release means onto a chosen area of skin and allowed to stiffen and harden for a fixed period of time. This stiffened composition is then removed from the surface of the skin and thereby removes the unwanted hair from that region of skin. The preferred depilatory composition is a commercially available water based contact adhesive AFFIX (Evode Ltd., Stafford, UK) which is applied as a foam and then spread over the desired area of skin using, say, a spatula, to a thickness determined by the properties of the hair to be removed. The film of adhesive stiffens as a volatile component, such as water, evaporates. Other polymer materials may also be used. The stiffened film layer may also be removed by the use of a flexible and/or adhesive strip which is applied to the stiffened film layer and once adhered to same, it is then used to remove said stiffened layer from the skin along with the unwanted hair. The depilatory composition may undergo a distinct change in appearance, e.g. change in colour, as it stiffens. The composition may also contain other components such as perfume, which may improve the appearance and/or condition of the skin. The pressurised container may be an aerosol can.
The side effects of pyridostigmine bromide oral solution are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

To report SUSPECTED ADVERSE REACTIONS, contact Athem LLC at 844-369-4671 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
BACKGROUND: Myocardial infarction poses major risks to human health because of their incredibly high rates of morbidity and mortality. Infarctions are more likely to develop as a result of dysregulation of cell death. Myrtenal can be considered for their bioactive beneficial activity in the context of cardiovascular pathologies and, particularly, in the protection toward oxidative stress followed by ischemic injury.
OBJECTIVE: This study aimed to put limelight on the antioxidant, anti-apoptotic, and antibacterial properties of Myrtenal.
METHODS: An in vitro model of oxidative stress-induced injury was entrenched in H9c2 cells using hydrogen peroxide, and the effects of Myrtenal were investigated. The MTT, cellular enzyme level, staining, and flow cytometry analysis were used to examine protective, antioxidant, and anti-apoptotic effects. The gene expressions were detected by qPCR. Antibacterial effect and biofilm formation were also done.
RESULT: The findings revealed that Myrtenal alone had negligible cytotoxic effects and that Myrtenal protects H9c2 against H2 O2 -induced cell death at micromolar concentrations. Myrtenal pre-treatment inhibited the generation of reactive oxygen species (ROS) as well as remarkably decreased the fluorescence intensity of ROS. Additionally, Myrtenal considerably increased the synthesis of antioxidant enzymes while dramatically decreasing the production of MDA and LDH. qPCR demonstrated the downregulation of Cas-9, TNF-α, NF-κB, P53, BAX, iNOS, and IL-6 expression while an upregulation of Bcl-2 expression in Myrtenal pre-treated groups. Myrtenal also holds the magnificent property of inhibiting bacterial growth.
CONCLUSION: Myrtenal ameliorates H2 O2 -induced cardiomyocyte injury and protects cardiomyocyte by inhibiting oxidative stress, inflammation, and apoptosis and may be a promise drug for the treatment of heart diseases.
Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 200 mg bid. This arm focuses on evaluating safety, tolerability, and pharmacokinetics (PK) at this dose.
With the premise that U.S. Veteran demographics reveal an aging population with significant mobility limitation and oxidative stress is tightly linked to both of these characteristics, a series of skeletal muscle/vascular studies are proposed. Specifically, in a series of recent studies the investigators' group has documented positive vascular consequences of antioxidant supplementation during exercise in older subjects that negatively impacted young people. Further provocative findings revealed that following exercise training the older subjects were now also negatively impacted by the antioxidant supplementation. These findings have implications for the understanding of the complex balance between the positive effects of exercise-based rehabilitation, exercise induced oxidative stress, aging, frailty, and subsequent mobility limitation. Therefore four specific aims are proposed that will answer the questions of where (I) oxidative stress is most prevalent in the elderly, why (II) oxidative stress occurs in the elderly, what (III) are the acute consequences of oxidative stress in the elderly, and finally how (IV) can exercise-induced oxidative stress as the result of exercise training in elderly be appropriately managed with exogenous antioxidant therapy to promote compliance and the positive outcome of increased mobility.
The application provides a method, a device, equipment and a storage medium for inquiring an object in close contact. The method comprises the following steps: and acquiring information of the target object. And acquiring the positioning information set of the target object from the communication subsystem according to the target query condition, the query starting time and the telephone number of the target object. And processing the positioning information set to obtain a track information set of the target object. And acquiring positioning information of the candidate contact object corresponding to each group of track information from the communication subsystem according to the track information set of the target object. And determining the closely contacted object of the target object from the candidate contact objects according to each set of track information and the positioning information of the corresponding candidate contact objects. Information of the closely contacted object of the target object is output. The method of the application improves the efficiency and accuracy of searching the closely contacted objects.
Hair growth promoting aerosol and shampoo compositions contain (3-carbomethoxypropyl) trimethyl ammonium chloride.  Typical examples described the preparation of an aerosol composition by dissolving (3-carbomethoxypropyl) trimethyl ammonium chloride, propylene glycol, and perfume in 50% ethanol followed by filling it in a pressure sprayer together with dichlorodifluoromethane, and the preparation of a shampoo by dissolving sesquioleic acid sorbitan and lanolin in polysorbate 80 to which an aqueous solution containing (3-carbomethoxypropyl) trimethyl ammonium chloride and sodium carboxymethyl cellulose is added.  The shampoo compositions may contain polyoxyethylene nonyl phenol or an alkanolamide and lanolin. A cream and oil are also described containing a non-ionic polyoxyethylene type detergent.ALSO:3 - Carbomethoxypropyl - trimethyl - ammonium chloride is prepared by reacting trimethylamine with methyl g -chlorobutyrate.ALSO:Hair growth compositions contain, as the active ingredient, (3-carbomethoxypropyl) trimethyl ammonium chloride.  Other nutrients, e.g. vitamins, amino acids and hormones, may be present.  The compositions can be applied in the form of lotions, cold creams, vanishing creams, pomades, hair oils, aerosols or shampoos.
BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is often comorbid with other medical conditions in adult patients. However, ADHD is extremely underdiagnosed in adults and little is known about the medical comorbidities in undiagnosed adult individuals with high ADHD liability. In this study we investigated associations between ADHD genetic liability and electronic health record (EHR)-based ICD-10 diagnoses across all diagnostic categories, in individuals without ADHD diagnosis history.
METHODS: We used data from the Estonian Biobank cohort (N = 111 261) and generated polygenic risk scores (PRS) for ADHD (PRSADHD) based on the ADHD genome-wide association study. We performed a phenome-wide association study (PheWAS) to test for associations between standardized PRSADHD and 1515 EHR-based ICD-10 diagnoses in the full and sex-stratified sample. We compared the observed significant ICD-10 associations to associations with (1) ADHD diagnosis and (2) questionnaire-based high ADHD risk analyses.
RESULTS: After Bonferroni correction (p = 3.3 × 10-5) we identified 80 medical conditions associated with PRSADHD. The strongest evidence was seen with chronic obstructive pulmonary disease (OR 1.15, CI 1.11-1.18), obesity (OR 1.13, CI 1.11-1.15), and type 2 diabetes (OR 1.11, CI 1.09-1.14). Sex-stratified analysis generally showed similar associations in males and females. Out of all identified associations, 40% and 78% were also observed using ADHD diagnosis or questionnaire-based ADHD, respectively, as the predictor.
CONCLUSIONS: Overall our findings indicate that ADHD genetic liability is associated with an increased risk of a substantial number of medical conditions in undiagnosed individuals. These results highlight the need for timely detection and improved management of ADHD symptoms in adults.
The study will last one year and is expected to include 120 patients with RVO and 120 control patients. The first 10 RVO patients visiting St. Erik's Eye Hospital with disease duration of maximum 3 months will be included in the study each month. The control patients will be chosen randomly by the Central Bureau of Statistics and matched for age and gender according to disease distribution known from previous studies. The control group will receive a letter with information of the study, informed consent form and details about the blood sampling procedure. Every month 50 patients in the control group will be invited to participate in the study. Only the first 10 control subjects will be included in the study. Each month a blood sample will be taken from 10 patients with RVO and 10 subjects in the control group. All the subjects will only have one blood sample taken during the study. Blood will be analyzed to measure the vitamin D level. Vitamin D levels will be compared at the end of the study between groups and evaluated according to the time of year for sampling. All the blood sampling will be done by the laboratory at Karolinska University Hospital. Participation in the study is completely voluntary. The details of the study has been reviewed and approved by the Ethics Committee.
Our study's objective is to evaluate the Virtual Agent Linked Intelligent Disease Assessment Tool Engine ("VALIDATE") system as a means to improve the affordability and ease, while maintaining the validity and feasibility, of collecting, assessing, and acting on Comprehensive Health History data.

Virtual Agents (VAs) are fully autonomous and embodied software agents that use both verbal (e.g. speech) and non-verbal modalities (e.g., gaze, gesturing) to simulate a clinician-patient encounter. These agents have already successfully shown advantages to patients for: entering family history data on their own, facilitating medication adherence, providing behavioral health information, serving as clinical interviewers, promoting breastfeeding, and educating about and motivating exercise and weight loss. The VALIDATE system has been developed to be a fully automated alternative to the currently extremely labor-intensive process of collecting and transcribing CHH data. VALIDATE will be evaluated for its capability to significantly diminish clinician time and cost to collect, review, analyze, and document accurate and complete certain CHH data directly from patients at home using their own personal desktop computers. VALIDATE will also be evaluated for its capability to identify valid clinical action, e.g. referral indications for familial cancer assessment based on American College of Medical Genetics and Genomics (ACMG)/National Society of Genetic Counselors (NSGC) and National Comprehensive Care Network (NCCN) Guidelines.
The investigators anticipate to undertaking a parallel group, randomised controlled trial of 106 ITP patients. One part of the participants are randomly selected to receive diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months), combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). The others are selected to receive high-dose of dexamethasone alone. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. The purpose of this study is to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule combining with high-dose dexamethasone therapy for the treatment of ITP.